Europe Non-Alcoholic Steatopatitis Market Overview, Development History, Strategic Assessment 2028

The Europe non-alcoholic steatopatitis market is expected to reach US$ 6,765.21 million by 2028 from US$ 496.83 million in 2021. The market is estimated to grow at a CAGR of 45.2% from 2021 to 2028.

Raising Awareness of Europe non-alcoholic steatopatitis market

Non-Alcoholic Steatohepatitis (NASH) remains a significantly under-recognized condition, yet its prevalence affects an estimated 115 million people globally. Increasing awareness among the general public and primary care physicians (PCPs) is crucial for early detection and establishing a structured referral pathway to specialists. By raising awareness, more individuals can be identified and directed to specialists for further evaluation, ultimately expanding the patient pool for appropriate care.

Significant efforts have been made to combat this lack of awareness. The NASH Education Program launched a public education campaign on June 12, 2018, coinciding with the inaugural “International NASH Day.” This initiative aimed to educate people about non-alcoholic fatty liver disease (NAFLD) and its more severe form, NASH. Building on this momentum, NASH 24X7, a dedicated digital platform, undertook several steps on June 12, 2019, for International NASH Day. Their efforts included providing support for healthcare professionals (HCPs), launching patient awareness campaigns, and issuing press and TV releases.

A key component of these patient education efforts involved NASH Crusaders of NASH 24X7 collaborating with HCPs across India. Together, they organized numerous small and large-scale workshops to educate the public on liver health and emphasize the importance of a healthy lifestyle in preventing NAFLD and NASH. Additionally, various public outreach initiatives, such as press releases and television programs utilizing both digital and print media, were employed to maximize reach on International NASH Day. These concerted efforts highlight a growing recognition of NASH, with the Europe non-alcoholic steatopatitis market, for instance, projected to experience substantial growth during the forecast period.

The Europe non-alcoholic steatopatitis market is a significant segment within the broader liver disease treatment landscape, driven by the increasing prevalence of obesity and related metabolic disorders. Here’s a breakdown of its segmentation and key players, based on the provided information:

Europe non-alcoholic steatopatitis market Segmentation:

Europe non-alcoholic steatopatitis market Product Type:

• • Vitamin E and Pioglitazone
  • Ocaliva (Obeticholic Acid)
  • Elafibranor
  • Selonsertib & Cenicriviroc (expected to be the fastest-growing segment)
  • Others (including other investigational and approved therapies)

Europe non-alcoholic steatopatitis market Application:

• • Treatment (dominated the market in 2020)
  • Diagnosis

Europe non-alcoholic steatopatitis market Sales Channel:

• • Hospital Pharmacy
  • Online Provider
  • Retail Pharmacy (dominated the market in 2020)

Europe non-alcoholic steatopatitis market Country:

• • Germany (dominated the market in 2020)
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Leading Companies in the Europe non-alcoholic steatopatitis market:

• Cadila Pharmaceutical
• Intercept Pharmaceutical
• Novartis AG
• Galmed Pharmaceutical
• GENFIT
• ONE WAY LIVER SI
• BioPredictive S.A.S
• Siemens Healthineers AG
• Laboratory Corporation of America Holdings

Additional Insights from Search Results: Europe non-alcoholic steatopatitis market

Market Size & Growth:As per our report Europe Non-Alcoholic Steatopatitis Market, the market size is valued at US$ 496.83 Million in 2021, projecting it to reach US$ 6,765.21 Million by 2028. This translates to a CAGR of approximately 45.2% during the forecast period.

Key Drivers: The increasing prevalence of obesity globally is a major growth factor for the NASH treatment market.

Challenges: A major challenge is the lack of appropriate, FDA-approved treatments that can halt or reverse the progression of hepatic fibrosis, cirrhosis, and hepatocellular carcinoma.

Emerging Trends:

• • Increased interest in non-invasive diagnostics.
  • Development of novel therapies and pharmacological treatments targeting various metabolic, inflammatory, and fibrotic pathways.
  • Shift towards combination therapies due to the complex pathogenesis of NASH.
  • Rising adoption of telemedicine and e-commerce platforms for healthcare products, driving the online providers segment.

Specific Company Activities:

• • Intercept Pharmaceuticals: Their lead product is Ocaliva (obeticholic acid, OCA), though its marketing authorization in Europe was revoked in August 2024. They were acquired by Alfasigma S.p.A.
  • Novartis AG: Has a development portfolio in non-viral liver diseases, including NASH, and has entered clinical collaborations to evaluate combination therapies.
  • Galmed Pharmaceuticals: Focused on developing Aramchol, with recent patent grants for combination therapy with Resmetirom. They are also exploring broader cardiometabolic indications.
  • GENFIT: Has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and a rapidly expanding R&D portfolio in liver diseases. Their product elafibranor (Iqirvo®) has recently received pricing and reimbursement approval in Italy.
  • ONE WAY LIVER S.L.: A biotechnology company offering diagnostic products and metabolomics services for liver diseases, including OWLiver for steatosis and NASH diagnosis.
  • BioPredictive S.A.S: Offers non-invasive diagnostic tests for liver diseases, including NASH-FibroTest, SteatoTest, and NashTest.
  • Siemens Healthineers AG & Laboratory Corporation of America Holdings (Labcorp): These companies are involved in broader healthcare diagnostics and services, which would include solutions and testing relevant to NASH diagnosis and monitoring.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.

Author’s Bio:

Suryakant Gadekar

Senior Market Research Expert at Business Market Insights